Prakash Neupane, MBBS

I am a medical oncologist who is focused on head and neck and thoracic oncology. I am also the director of the hematology-oncology fellowship and chair of the head and neck disease working group. The area of research is clinical research in head and neck / thoracic oncology. I have worked in small community as general hematology oncology and with NCI comprehensive cancer center, KU Cancer center since 2008 focused on head and neck and thoracic oncology.
In addition to clinical care, clinical research, I am also interested in graduate medical education. I am the director of fellowship working to expand training in cancer care for future academic physician as well as clinicians for community around Kansas City and rural Kansas. Recent addition of community track in the fellowship program is expected to increase hematology oncology physician in local community.

I am actively working as head and neck cancer disease working group chair. Several clinical trials are open in the head and neck cancer area including new innovative cell therapy, immune therapy other new novel drugs trials in head and neck cancers. I am interested to work on innovative trials immune altering clinical research. I am open to any collaboration with any translational researcher and industry for such innovative clinical research.

A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency

A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer

Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center

CASTLE thyroid tumor: A case report and literature review

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial

Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score < 1, 1-19, and >= 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting

Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease

Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.

Pembrolizumab Alone or With Chemotherapy for Squamous Head and Neck Cancer

A Phase III, randomized, open-label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Description A Phase II Pilot Study of ADP-A2M4 in Combination with Pembrolizumab for Advanced or Recurrent Head and Neck Cancer.

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Nav-Paclitaxel induction chemotherapy followed by cetuximab and concurrent radiation for locally advanced and platinum ineligible squamous head and neck carcinoma.

Pembrolizumab MK 3475 First Line treatment of recurrent metastatic head and neck squamous cell carcinoma.

Pembrolizumab (MK-3475) w/ or w/o lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with R/M

Randomized Double Blind Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)